BRCA1 Antibody | XW-7813

BRCA1 Antibody | XW-7813 | Gentaur UK, US & Europe Distribution

Host: Chicken

Reactivity: Human

Homology: N/A

Immunogen: 300-500

Research Area: Apoptosis, Cancer, Homeostasis

Tested Application: WB

Application: Breast and ovarian cancer susceptibility protein splice variant antibody can be used for the detection of Breast and ovarian cancer susceptibility protein splice variant by Western Blot.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 199.7 kDa (calculated)

Validation: N/A

Isoform: N/A

Purification: Immunoaffinity Purified

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Phosphate-Buffered Saline. No preservatives added.

Concentration: 1 mg/mL

Storage Condition: BRCA1 antibody can be stored at 4˚C for short term (weeks) . Long term storage should be at -20˚C. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: RNF53, Breast cancer type 1 susceptibility protein, RING finger protein 53, IRIS, PSCP, BRCAI, BRCC1, PNCA4, RNF53, BROVCA1, PPP1R53, Breast and ovarian cancer susceptibility protein splice variant

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This protein is a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC for BRCA1-associated genome surveillance complex. This protein product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complex. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants have been described for this gene but only some have had their full-length natures identified.